Heterozygous and Homozygous JAK2V617F States Modeled by Induced Pluripotent Stem Cells from Myeloproliferative Neoplasm Patients

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Saliba, Joseph ^a,b,c   Hamidi, Sofiane ^a,b,c   Lenglet, Gaëlle ^a,b,c   Langlois, Thierry ^a,b,c   Yin, Jingkui ^e   Cabagnols, Xénia ^a,b,c   Secardin, Lise ^a,b,c   Legrand, Céline ^a,b,c   Galy, Anne ^a   Opolon, Paule ^c   Benyahia, Baya ^d   Solary, Eric ^a,b,c   Bernard, Olivier A ^a,b,c   Chen, Longyun ^e   Debili, Najet ^a,b,c   Raslova, Hana ^a,b,c   Norol, Françoise ^a,b,c   Vainchenker, William ^a,b,c   Plo, Isabelle ^a,b,c   Di Stefano, Antonio ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e BGI SHENZHEN   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEAT SHOCK PROTEIN 90; JANUS KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; THROMBOPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASXL1 GENE; CELL GROWTH; CELL LINE; CHROMOSOME 20; CLONE; COLONY FORMATION; CONTROLLED STUDY; ERYTHROID CELL; GENE; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; JAK2 GENE; MEGAKARYOCYTE; MOUSE; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PLURIPOTENT STEM CELL; POLYCYTHEMIA VERA; SIGNAL TRANSDUCTION;

CELLS, CULTURED; ERYTHROPOIETIN; HUMANS; INDUCED PLURIPOTENT STEM CELLS; JANUS KINASE 2; MYELOPROLIFERATIVE DISORDERS; PHOSPHATIDYLINOSITOL 3-KINASES; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; THROMBOPOIETIN;

EID: 84884172929     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074257     Document Type: Article

References (40)

1. James C, Ugo V, Le Couédic, Staerk J, Delhommeau F, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148. doi:10.1038/nature03546. PubMed: 15793561.
2. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779-1790. doi:10.1056/NEJMoa051113. PubMed: 15858187.
3. Dupont S, Massé A, James C, Teyssandier I, Lécluse Y, et al. (2007) The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 110: 1013-1021. doi:10.1182/blood-2006-10-054940. PubMed: 17389763.
4. Scott LM, Scott MA, Campbell PJ, Green AR, (2006) Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 108: 2435-2437. doi:10.1182/blood-2006-04-018259. PubMed: 16772604.
5. Shih AH, Abdel-Wahab O, Patel JP, Levine RL, (2012) The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 12: 599-612. doi:10.1038/nrc3343. PubMed: 22898539.
6. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA, (2011) New mutations and pathogenesis of myeloproliferative neoplasms. Blood 118: 1723-1735. doi:10.1182/blood-2011-02-292102. PubMed: 21653328.
7. Grskovic M, Javaherian A, Strulovici B, Daley GQ, (2011) Induced pluripotent stem cells--opportunities for disease modelling and drug discovery. Nat Rev Drug Discov 10: 915-929. PubMed: 22076509.
8. Kumano K, Arai S, Hosoi M, Taoka K, Takayama N, et al. (2012) Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood 119: 6234-6242. doi:10.1182/blood-2011-07-367441. PubMed: 22592606.
9. Ye Z, Zhan H, Mali P, Dowey S, Williams DM, et al. (2009) Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 114: 5473-5480. doi:10.1182/blood-2009-04-217406. PubMed: 19797525.
10. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872. doi:10.1016/j.cell.2007.11.019. PubMed: 18035408.
11. Takayama N, Nishikii H, Usui J, Tsukui H, Sawaguchi A, et al. (2008) Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. Blood 111: 5298-5306. doi:10.1182/blood-2007-10-117622. PubMed: 18388179.
12. Klimchenko O, Mori M, Distefano A, Langlois T, Larbret F, et al. (2009) A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cell-derived primitive hematopoiesis. Blood 114: 1506-1517. doi:10.1182/blood-2008-09-178863. PubMed: 19478046.
13. Vodyanik MA, Bork JA, Thomson JA, Slukvin II, (2005) Human embryonic stem cell-derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. Blood 105: 617-626. doi:10.1182/blood-2004-04-1649. PubMed: 15374881.
14. Prchal JF, Axelrad AA, (1974) Letter: Bone-marrow responses in polycythemia vera. N Engl J Med 290: 1382. doi:10.1056/NEJM197406132902417. PubMed: 4827655.
15. Reddy MM, Deshpande A, Sattler M, (2012) Targeting JAK2 in the therapy of myeloproliferative neoplasms. Expert Opin Ther Targets 16: 313-324. doi:10.1517/14728222.2012.662956. PubMed: 22339244.
16. LaFave LM, Levine RL, (2012) JAK2 the future: therapeutic strategies for JAK-dependent malignancies. Trends Pharmacol Sci 33: 574-582. doi:10.1016/j.tips.2012.08.005. PubMed: 22995223.
17. Loh YH, Hartung O, Li H, Guo C, Sahalie JM, et al. (2010) Reprogramming of T cells from human peripheral blood. Cell Stem Cell 7: 15-19. doi:10.1016/j.stem.2010.06.004. PubMed: 20621044.
18. Staerk J, Dawlaty MM, Gao Q, Maetzel D, Hanna J, et al. (2010) Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell 7: 20-24. doi:10.1016/j.stem.2010.06.002. PubMed: 20621045.
19. Takayama N, Nishimura S, Nakamura S, Shimizu T, Ohnishi R, et al. (2010) Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. J Exp Med 207: 2817-2830. doi:10.1084/jem.20100844. PubMed: 21098095.
20. Seki T, Yuasa S, Oda M, Egashira T, Yae K, et al. (2010) Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 7: 11-14. doi:10.1016/j.stem.2010.06.003. PubMed: 20621043.
21. Quinlan AR, Boland MJ, Leibowitz ML, Shumilina S, Pehrson SM, et al. (2011) Genome sequencing of mouse induced pluripotent stem cells reveals retroelement stability and infrequent DNA rearrangement during reprogramming. Cell Stem Cell 9: 366-373. doi:10.1016/j.stem.2011.07.018. PubMed: 21982236.
22. Gore A, Li Z, Fung HL, Young JE, Agarwal S, et al. (2011) Somatic coding mutations in human induced pluripotent stem cells. Nature 471: 63-67. doi:10.1038/nature09805. PubMed: 21368825.
23. Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, et al. (2012) ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22: 180-193. doi:10.1016/j.ccr.2012.06.032. PubMed: 22897849.
24. Maclean GA, Menne TF, Guo G, Sanchez DJ, Park IH, et al. (2012) Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc Natl Acad Sci U S A 109: 17567-17572. doi:10.1073/pnas.1215468109. PubMed: 23045682.
25. Li LB, Chang KH, Wang PR, Hirata RK, Papayannopoulou T, et al. (2012) Trisomy correction in down syndrome induced pluripotent stem cells. Cell Stem Cell 11: 615-619. doi:10.1016/j.stem.2012.08.004. PubMed: 23084023.
26. Davies C, Yip BH, Fernandez-Mercado M, Woll PS, Agirre X, et al. (2013) Silencing of ASXL1 impairs the granulomonocytic lineage potential of human CD34(+) progenitor cells. Br J Haematol.
27. Chen E, Beer PA, Godfrey AL, Ortmann CA, Li J, et al. (2010) Distinct clinical phenotypes associated with JAK2V617F reflect differential. Stat 1 signaling. Cancer Cell 18: 524-535.
28. Mead AJ, Rugless MJ, Jacobsen SE, Schuh A, (2012) Germline JAK2 mutation in a family with hereditary thrombocytosis. N Engl J Med 366: 967-969. doi:10.1056/NEJMc1201858. PubMed: 22397670.
29. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, et al. (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29: 789-796. doi:10.1200/JCO.2011.36.9280. PubMed: 21220608.
30. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, et al. (2012) Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 120: 1202-1209. doi:10.1182/blood-2012-02-414631. PubMed: 22718840.
31. Marubayashi S, Koppikar P, Taldone T, Abdel-Wahab O, West N, et al. (2010) HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest 120: 3578-3593. doi:10.1172/JCI42442. PubMed: 20852385.
32. Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, et al. (2011) Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 118: 2069-2076. doi:10.1182/blood-2011-01-330563. PubMed: 21725052.
33. Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, et al. (2012) Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med 209: 259-273. doi:10.1084/jem.20111694. PubMed: 22271575.
34. Bogani C, Bartalucci N, Martinelli S, Tozzi L, Guglielmelli P, et al. (2013) mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. PLOS ONE 8: e54826. doi:10.1371/journal.pone.0054826. PubMed: 23382981.
35. Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, et al. (2010) Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115: 3109-3117. doi:10.1182/blood-2009-04-214957. PubMed: 20130243.
36. Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, et al. (2009) Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 114: 5024-5033. doi:10.1182/blood-2009-05-222133. PubMed: 19828702.
37. Jedidi A, Marty C, Oligo C, Jeanson-Leh L, Ribeil JA, et al. (2009) Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. Blood 114: 1842-1851. doi:10.1182/blood-2008-09-176875. PubMed: 19589925.
38. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, et al. (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110: 1092-1097. doi:10.1182/blood-2007-04-083501. PubMed: 17488875.
39. Mali P, Ye Z, Hommond HH, Yu X, Lin J, et al. (2008) Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts. Stem Cells 26: 1998-2005. doi:10.1634/stemcells.2008-0346. PubMed: 18511599.
40. Debili N, Coulombel L, Croisille L, Katz A, Breton Gorius J, et al. (1996) Characterization of a bipotent erythro-megakaryocytic progenitor in human bone marrow. Blood 88: 1284-1296. PubMed: 8695846.